The global market for treatments for syndromes of progressive ataxia and
weakness disorders was valued at nearly $14 billion in 2011 and should reach
nearly $15 billion in 2012. Total market value is expected to reach nearly
$23.5 billion in 2017 after increasing at a five-year compound annual growth
rate (CAGR) of 9.4%.
Treatments for progressive weakness syndromes should total nearly $14.6
billion in 2012 and $22.8 billion in 2017, a CAGR of 9.4%.
Treatments for multiple sclerosis should total nearly $12.6 billion in
2012 and $19.5 billion in 2017, a CAGR of 9.2%.
SUMMARY FIGURE
GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS,
2010-2017 ($ MILLIONS)
Source: BCC Research
STUDY OBJECTIVES
BCC's goal in conducting this study is to provide an overview of the current
and future characteristics of the global market for treatments of
neurodegenerative (i.e., progressive ataxia and weakness) disorders. The key
objective is to present a comprehensive analysis and the future direction of
treatments for these disorders as the market efforts toward drug and therapy
development evolve.
This report explores present and future strategies within the progressive
ataxia and weakness disorders market, which includes treatments and therapies
for dysfunctions, including progressive ataxia and progressive weakness
disorder syndromes. The market's improvisation, setbacks and needs are also
discussed. The comparisons, usage, advantages and disadvantages of different
types of technologies, including small-molecule and monoclonal antibodies, are
also presented.
A detailed analysis of the industry structure has been conducted. Revenues
are broken down by the neurodegenerative dysfunction. Sales figures are
estimated for the five-year period from 2012 through 2017.
The report discusses applications for neurodegenerative disorder treatment and
therapy technologies, with emphasis on small-molecule and monoclonal
antibodies technology. The report also covers significant patents and their
allotments in each category.
REASONS FOR DOING THIS STUDY
Extensive research in the field of progressive ataxia and weakness disorders
as well as collaborations with research institutes have highlighted the
importance of understanding the nature of these disorders. New technology
development is providing modifying therapies for the late stages of these
disorders. Collaborations among research institutes and pharmaceutical
companies are becoming more common, as state-of-the-art technology is being
explored to develop more-efficient products and therapies.
R&D spending, increasing competition, patent expiries and new technologies are
shifting the market in a new direction. The market's overall revenue has
increased from 2009 to 2011, and it continues to show growth, as new
advancements, product launches and collaborations will have positive
influences for the foreseeable future. This study looks at most of the
systems affected by these factors.
Acquisition strategies and company collaborations are also covered in this
report. This study discusses the strength and weaknesses of each technology
in light of the new developments, growing competition and changing customer
needs.
SCOPE OF THE STUDY
The scope of this study encompasses the neurodegenerative (i.e., progressive
ataxia and weakness) disorders in the pharmaceutical and biotechnology
markets. BCC analyzes each market and its applications, the regulatory
environments, and the technologies involved, as well as market projections and
market shares. Technological issues include the latest trends and
developments. The emerging market for enzyme inhibitors includes such
countries as India, China, Japan, South Korea, Taiwan, Canada, Africa,
Australia and New Zealand.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
study. BCC conducted a comprehensive literature search, which included
technical newsletters and journals, among other sources. Data were collected
through interviews and correspondence with technical experts at companies that
manufacture enzyme inhibitors. Projections were based on estimates that were
calculated such using information as the current number of end users,
potential end users, mergers and acquisitions, and market trends.
INFORMATION SOURCES
Many companies within the industry were surveyed to obtain data for this
study. These included manufacturers and end users of enzyme inhibitors in
therapeutic categories and various disease-sector industries. Data were
gathered from various industry sources. BCC spoke with officials within the
industry and also reviewed newsletters, company literature and product
literature, as well as a host of technical articles, journals, indices and
abstracts. Exhaustive investigations of databases by key terminology were
completed. In addition, data were compiled from current financial, trade and
government sources.
ABOUT THE AUTHOR
A team of professionals in the biotechnology industry has carried out this
study. Its project manager is Shalini S. Dewan, who holds a Master's
degree in pharmaceutical chemistry and has more than 14 years of industry
experience. She has covered such research topics as compounds of potential
pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini
was awarded a Gold Medal by the Prime Minister of India for her work, and she
has collaborated with top companies in India and in the U.S.
Table of Contents
Table of Contents
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Weakness Disorders
Chapter - 1: INTRODUCTION - Complimentary
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR
RELATED BCC RESEARCH REPORTS
BCC ON-LINE SERVICES
DISCLAIMER
Chapter - 2: EXECUTIVE SUMMARY
Table Summary: GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS
DISORDERS, THROUGH 2017
Figure Summary: GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS
DISORDERS, 2010-2017
Chapter - 3: OVERVIEW
DEFINITIONS
CLASSIFICATION
PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS
DIAGNOSTIC TESTS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS
Chapter - 4: REGULATORY ASPECTS
DRUG APPROVALS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS
REGULATORY DEVELOPMENTS OF PRODUCTS USED TO TREAT PROGRESSIVE ATAXIA AND
WEAKNESS DISORDERS
Chapter - 5: NEW DEVELOPMENTS
Table 6: NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND
WEAKNESS DISORDERS, 2012
Table 7: NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND
WEAKNESS DISORDERS, 2011
Table 8: NEW DEVELOPMENTS IN THE TREATMENT OF PROGRESSIVE ATAXIA AND
WEAKNESS DISORDERS, 2010
ADDITIONAL DRIVERS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS DRUG
MARKET
FACTORS GOVERNING THE MARKET
COLLABORATIONS, MERGERS AND ACQUISITIONS
Chapter - 10: COMPANY PROFILES
ABBOTT LABORATORIES
ACORDA THERAPEUTICS INC.
ACTAVIS ELIZABETH
ALLON THERAPEUTICS INC
AMERICAN REGENT INC.
APOTEX INC.
APOTHECA, INC.
APP PHARMACEUTICALS
ASTELLAS PHARMA INC.
ASTRAZENECA GMBH
AUROBINDO PHARMA LTD
BAXTER INTERNATIONAL INC.
BIOGEN IDEC
BOEHRINGER INGELHEIM LTD.
BRISTOL-MYERS SQUIBB
BRYANT RANCH PREPACK
CADILA HEALTHCARE LTD.
CARACO PHARMACEUTICAL LABORATORIES
CARDINAL HEALTH
COGNITION PHARMACEUTICALS LLC
CSL BEHRING
DR. REDDY'S LABORATORIES LIMITED
EISAI CO. LTD
ELAN PHARMA INTERNATIONAL LIMITED
ELI LILLY AND COMPANY
EMD MILLIPORE HEADQUARTERS
ENDO PHARMACEUTICALS INC
GLAXOSMITHKLINE PLC.
GLENMARK GENERICS LIMITED
H. LUNDBECK A/S
HAMELN PHARMACEUTICALS LTD
HOSPIRA INC.
INTELLECT NEUROSCIENCES INC.
JAZZ PHARMACEUTICALS PLC.
LEXICON PHARMACEUTICALS INC.
MAJOR PHARMACEUTICALS
MERCK SERONO
MERCK SHARP
MERZ PHARMA GMBH
MOMENTA PHARMACEUTICALS
MYLAN PHARMACEUTICALS
NEUREN PHARMACEUTICALS LTD.
NEUROSEARCH A/S
NOSCIRA, S.A.
NOVARTIS AG
ORCHID CHEMICALS
ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.
PAR PHARMACEUTICALS
PERRIGO COMPANY
PFIZER INC.
PHARNEXT
PHYSICIANS TOTAL CARE, INC.
PLIVA HRVATSKA D.O.O.
PROMETHEUS
RANBAXY LABORATORIES LIMITED
ROCHE HOLDING LTD
ROXANE LABORATORIES INC.
SANDOZ INTERNATIONAL GMBH
SANOFI
SANTHERA PHARMACEUTICALS
SHIONOGI
SUN PHARMA
TAJ PHARMACEUTICALS LIMITED
TAKEDA PHARMACEUTICAL COMPANY LIMITED
TERCICA, INC
TEVA PHARMACEUTICAL INDUSTRIES LTD
TORRENT PHARMA
UCB S.A.
UDL LABORATORIES
UPSHER-SMITH LABORATORIES
WATSON PHARMACEUTICALS INC.
WEST-WARD PHARMACEUTICAL
Chapter - 11: APPENDIX I: ABBREVIATIONS
Show Details
List of Tables
Summary Table: GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS
DISORDERS, THROUGH 2017
Table 1: CLASSIFICATION BY PRIMARY DYSFUNCTION
Table 2: ABBREVIATED APPROVALS AND NEW DRUG APPROVALS FOR PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS, 2012
Table 3: NEW DRUG APPLICATIONS FOR THE PROGRESSIVE ATAXIA AND WEAKNESS
DISORDERS
Table 4: SAFETY ALERTS, 2010-MARCH 2012
Table 5: RECALLS FOR DRUGS USED TO TREAT PROGRESSIVE ATAXIA AND WEAKNESS
DISORDERS, 2010 - MARCH 2012
Table 6: NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND
WEAKNESS DISORDERS, 2012
Table 7: NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND
WEAKNESS DISORDERS, 2011
Table 8: NEW DEVELOPMENTS IN THE TREATMENT OF PROGRESSIVE ATAXIA AND
WEAKNESS DISORDERS, 2010
Table 9: GLOBAL REVENUES OF DRUG PRODUCTS FOR THE TREATMENT OF
NEURODEGENERATIVE DYSFUNCTIONS, THROUGH 2017
Table 10: MARKET SHARE OF DRUGS USED FOR THE TREATMENT OF
NEURODEGENERATIVE DISORDERS BY DYSFUNCTIONS, 2011
Table 11: GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017
Table 12: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS, 2011
Table 13: MARKET FOR DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS BY REGION, THROUGH 2017
Table 14: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS BY REGION, 2011
Table 15: GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, THROUGH 2017
Table 16: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2011
Table 17: PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY DISEASE TYPE,
THROUGH 2017
Table 18: PROGRESSIVE WEAKNESS DRUG MARKET BY DISEASE TYPE, 2011
Table 19: PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY REGION, THROUGH
2017
Table 20: PROGRESSIVE WEAKNESS DRUG MARKET BY REGION, 2011
Table 21: AMYOTROPHIC LATERAL SCLEROSIS DRUG MARKET BY REGION, THROUGH
2017
Table 22: PROGRESSIVE BULBAR PALSY DRUG MARKET BY REGION, THROUGH 2017
Table 23: HEREDITARY SPASTIC PARAPLEGIA DRUG MARKET BY REGION, THROUGH
2017
Table 24: HEREDITARY NEUROPATHY DRUG MARKET BY REGION, THROUGH 2017
Table 25: MULTIPLE SCLEROSIS DRUG MARKET BY REGION, THROUGH 2017
Table 26: PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY TECHNOLOGY,
THROUGH 2017
Table 27: PROGRESSIVE WEAKNESS MARKET BY TECHNOLOGY, 2011
Table 28: MULTIPLE SCLEROSIS DRUG MARKET BY TECHNOLOGY, THROUGH 2017
Table 29: MULTIPLE SCLEROSIS DRUG MARKET DISTRIBUTION BY TECHNOLOGY, 2011
Table 30: LEADING MANUFACTURERS AND SUPPLIERS OF DRUGS AND THERAPIES FOR
AMYOTROPHIC LATERAL SCLEROSIS
Table 31: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS AMYOTROPHIC
LATERAL SCLEROSIS DRUGS, 2011
Table 32: LEADING MANUFACTURERS AND SUPPLIERS OF PROGRESSIVE BULBAR
PALSY DRUGS AND THERAPIES
Table 33: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF PROGRESSIVE
BULBAR PALSY DRUGS, 2011
Table 34: LEADING MANUFACTURERS AND SUPPLIERS OF HEREDITARY SPASTIC
PARAPLEGIA DRUGS AND THERAPIES
Table 35: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY
SPASTIC PARAPLEGIA DRUGS, 2011
Table 36: LEADING MANUFACTURERS AND SUPPLIERS OF HEREDITARY NEUROPATHY
DRUGS AND THERAPIES
Table 37: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY
NEUROPATHIES DRUGS, 2011
Table 38: LEADING MANUFACTURERS AND SUPPLIERS MULTIPLE SCLEROSIS DRUGS
AND THERAPIES
Table 39: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MULTIPLE
SCLEROSIS DRUGS, 2011
Table 40: TOTAL NUMBER OF PATENTS BY YEAR, 2010-MARCH 2012
Table 41: PATENTS BY DISEASE CATEGORY, 2010 - MARCH 2012
Table 42: PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY DISEASE TYPE, 2010
- 2012
Table 43: PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT THE ON BRAIN AND
SPINAL CORD SYNDROMES BY DISEASE TYPE, 2010 - 2012
Table 44: U.S. PATENTS BY COUNTRY FOR PROGRESSIVE ATAXIA SYNDROMES,
2010-2012
Table 45: PATENT SHARES BY COUNTRY FOR PROGRESSIVE ATAXIA SYNDROMES,
2010 - 2012
Table 46: U.S. PATENTS BY COUNTRY FOR PROGRESSIVE WEAKNESS AND EFFECT ON
THE BRAIN AND SPINAL CORD SYNDROMES, 2010 - 2012
Table 47: PATENT SHARES BY COUNTRY FOR PROGRESSIVE WEAKNESS AND EFFECT
ON THE BRAIN AND SPINAL CORD SYNDROMES, 2010 - 2012
Table 48: U.S. PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY COMPANY, 2010
- 2012
Table 49: U.S. PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN
AND SPINAL CORD SYNDROMES BY COMPANY, 2010-2012
Table 50: PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY ASSIGNEE, 2010-2012
Table 51: PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND
SPINAL CORD SYNDROMES BY ASSIGNEE, 2010 - 2012
List of Figures
Summary Figure: GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS
DISORDERS, 2010-2017
Figure 1: GLOBAL REVENUES OF DRUG PRODUCT FOR THE TREATMENT OF
NEURODEGENERATIVE DYSFUNCTIONS, 2010-2017
Figure 2: MARKET SHARE OF DRUG USED FOR THE TREATMENT OF
NEURODEGENERATIVE DISORDERS BY DYSFUNCTION, 2011
Figure 3: GLOBAL SALES OF DRUG PRODUCT FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS, 2010-2017
Figure 4: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS, 2011
Figure 5: MARKET FOR DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS BY REGION, 2010-2017
Figure 6: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS BY REGION, 2011
Figure 7: GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2010-2017
Figure 8: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE
ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2011
Figure 9: PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY DISEASE TYPE,
2010-2017
Figure 10: PROGRESSIVE WEAKNESS DRUG MARKET BY DISEASE TYPE, 2011
Figure 11: PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY REGION, 2010-2017
Figure 12: PROGRESSIVE WEAKNESS DRUG MARKET BY REGION, 2011
Figure 13: AMYOTROPHIC LATERAL SCLEROSIS DRUG MARKET BY REGION, 2010-2017
Figure 14: PROGRESSIVE BULBAR PALSY DRUG MARKET BY REGION, 2010-2017
Figure 15: HEREDITARY SPASTIC PARAPLEGIA DRUG MARKET BY REGION, 2010-2017
Figure 16: HEREDITARY NEUROPATHY DRUG MARKET BY REGION, 2010-2017
Figure 17: MULTIPLE SCLEROSIS DRUG MARKET BY REGION, 2010-2017
Figure 18: PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY TECHNOLOGY,
2010-2017
Figure 19: PROGRESSIVE WEAKNESS MARKET BY TECHNOLOGY, 2011
Figure 20: MULTIPLE SCLEROSIS DRUG MARKET BY TECHNOLOGY, 2010-2017
Figure 21: MULTIPLE SCLEROSIS DRUG MARKET DISTRIBUTION BY TECHNOLOGY,
2011
Figure 22: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF
AMYOTROPHIC LATERAL SCLEROSIS DRUGS, 2011
Figure 23: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF
PROGRESSIVE BULBAR PALSY DRUGS, 2011
Figure 24: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY
SPASTIC PARAPLEGIA DRUGS, 2011
Figure 25: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY
NEUROPATHY DRUGS, 2011
Figure 26: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MULTIPLE
SCLEROSIS, DRUGS 2011
Figure 27: NUMBER OF PATENTS BY YEAR, 2010 - MARCH 2012
Figure 28: PATENTS BY DISEASE CATEGORY, 2010 - MARCH 2012
Figure 29: PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY DISEASE TYPE,
2010 - 2012
Figure 30: PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON BRAIN AND
SPINAL CORD SYNDROMES BY DISEASE TYPE, 2010 - 2012
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Weakness Disorders published by BCC Research in October 18, 2012. This report consists of 144 Pages and the price starts from US $ 4400.
